Cancer patients receiving chemotherapy understand there is a risk of hair loss involved. In fact, along with nausea, hair loss is the most common and well known side effect of cancer drugs. Cancer paitents tolerate hair loss as a side effect because of the hope that the drug will save their lives and the knowledge that their hair will grow back after cancer treatment.
But a growing number of lawsuits filed against the makers of Taxotere allege that the company failed to warn patients that Taxotere may cause permanent hair loss. The lawsuits also claim that the drug manufacturer actively encouraged doctors to use Taxotere despite its risks and despite the availability of other, safer cancer treatments.
Taxotere was first approved by the FDA in 1996. It was a more powerful version of another chemotherapy drug that had already been approved for use. Taxotere has been approved for the treatment of metastatic prostate cancer, non-small cell lung cancer, neck and head cancer, advance stomach cancer and breast cancer. It is also being investigated as a possible treatment for other cancers, including small cell lung cancer and pancreatic cancer.